Social media footage of star-studded Super Bowl LV events over the weekend almost makes it look like the pandemic is over.
Social media footage of star-studded Super Bowl LV events over the weekend almost makes it look like the pandemic is over.
A traffic case involving Las Vegas Raiders player Josh Jacobs was closed Monday after he completed community service and paid a fine stemming from a vehicle crash in January near McCarran International Airport, his lawyers said. The 23-year-old running back mentored at a Boys & Girls Club and paid a $500 fine to resolve a failure to exercise due care traffic violation, said his attorneys, David Chesnoff and Richard Schonfeld. Jacobs received several stitches for a cut forehead and was initially also charged with driving under the influence after the 2019 Acura NSX he was driving crashed early Jan. 4 into a tunnel wall at the Las Vegas airport.
J.C. Hassenauer will get a shot at being the potential replacement for retired Pittsburgh Steelers center Maurkice Pouncey. The Steelers signed the 25-year-old Hassenauer to a one-year contract on Monday. Hassenauer, who appeared in 15 games for the Steelers in 2020 and made four starts, was an exclusive rights free agent.
The Miami Dolphins late Monday agreed on the parameters of a trade for troubled but talented offensive tackle Isaiah Wilson, who played just three offensive snaps as a rookie even though he was the Tennessee Titans’ first-round draft pick, the Miami Herald has confirmed.
The best Amazon deals to take advantage of today include a top-rated TLC TV, a robot vacuum that's worth every cent and more—shop our top picks.
Consumer group Which? staged a sting operation to investigate fake Google reviews in the UK.
NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today the successful completion and settlement of its US$110 million private placement led by a strategic US investor group, that was announced on Tuesday, March 2, 2021. The US$110 million (A$138 million) was raised via the issue of 60 million shares at A$2.30 per share, and was led by a strategic investment from the principals of SurgCenter Development, one of the largest private operators of ambulatory surgical centers in the US specializing in spine, orthopaedic and total joint procedures. Based on the US$110 million private placement, pro-forma cash-on-hand at December 31, 2020 would be approximately US$187.5 million. As announced on Tuesday, March 2, 2021, the use of the proceeds from the capital raising include: Operational and regulatory initiatives in support of the Company’s activities for regulatory meetings with United States Food & Drug Administration (FDA) in the coming quarters. These activities relate to its product candidates for steroid-refractory acute graft versus host disease (SR-aGvHD) in children, chronic heart failure and chronic lower back pain.Building commercial inventory of remestemcel-L ahead of potential approval for SR-aGvHD in children.Continuing to invest in manufacturing optimization and scale-up of rexlemestrocel-L and remestemcel-L platforms for larger market opportunities. About Mesoblast Mesoblast is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2040 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has completed Phase 3 trials of rexlemestrocel-L for advanced chronic heart failure and chronic low back pain. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast Forward-Looking Statements This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Not an offer of securities This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions registered under the Securities Act or exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws. Release authorized by the Chief Executive. For more information, please contact: Corporate Communications / Investors Paul Hughes T: +61 3 9639 6036 E: firstname.lastname@example.org Media Kristen Bothwell T: +1 917 613 5434 E: email@example.com
Kamloops residents can help fund the much-needed programs and services at the Mustard Seed by grabbing a slice of pizza next week. From March 15 to March 21, $5 from every $30 purchase at the local Pizza Now will go to The Mustard Seed Kamloops during the store’s inaugural YKA Pizza Week. “Kamloops has been awesome to me over the years and have provided me the opportunity to give back to those that need the help. I want to make this an annual event so I can give back as much as possible,” Pizza Now president Rocky Hunter said. Additionally, customers can purchase a $2 pizza slice certificate in advance of YKA Pizza Week at Pizza Now or at The Mustard Seed’s Thrift Store, downtown at 342 Seymour St. Half the proceeds from each certificate sold goes directly to The Mustard Seed and purchasers can redeem the certificate for a slice at Pizza Now’s 1415 Hillside Drive location in Dufferin. “Rocky has never hesitated to step up and do more than his share when it comes to donating to The Mustard Seed Kamloops,” said Kelly Thomson, managing director for The Mustard Seed. “We are thrilled to be the beneficiary of his YKA Pizza Week fundraiser because the funds donated will remain here in Kamloops and will go a long way in helping support and build our programs and initiatives to help many in our community.” As YKA Pizza Week coincides with spring break for most schools within School District 73, Pizza Now is also thanking teachers by offering them free 12-inch pizzas during YKA Pizza Week with proof of a teacher’s certificate. The Mustard Seed is a Christian non-profit organization that has been caring for individuals experiencing homelessness and poverty since 1984. Its outreach centre is downtown at 181 West Victoria St. Michael Potestio, Local Journalism Initiative Reporter, Kamloops This Week
The new policy could give Biden a political boost in Florida, where Venezuelans spent years lobbying then-President Trump against deportation.
The CDC maintains that Americans should refrain from traveling, referring to the organization's travel guidance last updated on Feb. 16.
Former 16-year major league relief pitcher Rheal Cormier died of cancer on Monday, the Philadelphia Phillies announced. Cormier pitched for five different teams but spent the most time -- six seasons -- with the Phillies. Cormier was drafted by the Cardinals in 1988 and spent his first four major league seasons in St. Louis.
LOS ANGELES — The second of two defendants accused of using bogus transcripts and ghostwritten essays to help foreigners gain admission to U.S. colleges, allowing the applicants to fraudulently obtain student visas, has surrendered to federal authorities, prosecutors said. Yi Chen, 33, pleaded not guilty Monday to charges in a 21-count grand jury indictment that alleges conspiracy, visa fraud and aggravated identity theft, the U.S. Attorney's Office said in a statement. His co-defendant, Yixin Li, 28, surrendered March 2 and also pleaded not guilty. The two Southern California men are accused in a scheme to get foreigners into colleges, which allowed them to fraudulently get visas to enter or remain in the United States, prosecutors said. The indictment alleges that Chen and Li owned so-called educational consulting companies in the southern California cities of Alhambra and Arcadia that charged foreign students thousands of dollars for “guaranteed” admission to a college that would lead to the issuance of an F-1 student visa. The pair prepared application packages that used fake transcripts and they hired people to impersonate the prospective student to take standardized tests, according to the court documents. The indictment lists a number of foreign nationals for whom Chen and Li allegedly obtained transcripts, which helped the students gain admission to schools including New York University, Columbia University, Boston College, and several University of California campuses. Chen was ordered detained pending trial, which was scheduled for May 4. Li remains in custody and his trial is set for April 27. The Associated Press
The following are the top stories on the business pages of British newspapers. - Secondary school pupils in England who feel anxious about wearing masks in school will not be forced to do so, the children's minister has said. - UK has been warned not to send a dreadful message to the rest of the world by backing a controversial Australian former minister with a much-criticised climate change record to run the Organisation for Economic Co-operation and Development.
Prices start at just $11
After the wave: a decade of grieving for a daughter lost to the Japanese tsunamiNoriyuki Suzuki returns to the spot where his daughter was swept to her death with her schoolmates Noriyuki Suzuki’s daughter, Mai, aged 12, was killed when the wave reached her primary school. Photograph: Kazuma Obara
Viacom International Studios has inked a first-look deal with South Korean production studio Something Special. Under the deal, VIS will have exclusive first-look rights to globally represent and co-develop up to 10 of Something Special’s top unscripted and factual entertainment formats. Founded by Jin Woo Hwang, the company acts as a bridge between content creators […]
NEW YORK — A person with direct knowledge of the move says the New York Jets placed the franchise tag on safety Marcus Maye, a steady playmaker and leader with whom the team hopes to work out a long-term deal. The move Monday night was expected and prevents Maye from becoming an unrestricted free agent when the new league year starts on March 17. NFL teams have until Tuesday at 4 p.m. EST to use the tag on a pending free agent. The person spoke to The Associated Press on condition of anonymity because the team hadn’t announced the move. ESPN first reported the Jets’ plan to use the franchise tag. The tag for a safety is expected to be worth around $10.5 million this year. By using the franchise tag, the sides have until July 15 to work out a new contract or Maye would have to sign the franchise tag tender to play in 2021. Maye, who turns 28 on Tuesday, joins Denver safety Justin Simmons as players to be franchise tagged this off-season. He's also the first Jets player to be tagged since Muhammad Wilkerson in 2016. Wilkerson was signed to a long-term contract later that summer, and that's the hope for both sides with Maye — whom general manager Joe Douglas said in January would be a top priority for the team this off-season. The 2017 second-round pick out of Florida has been a key presence on the field and in the locker room since joining the Jets and was voted the team MVP by teammates last season. Maye was second on New York with 78 tackles to go along with two interceptions, two sacks, two forced fumbles, a fumble recovery and a team-leading 11 passes defenced. Maye also displayed his versatility, playing in coverage as well as close to the line of scrimmage — taking over the role previously held by Jamal Adams. Those qualities would appear to be ideal fits in new Jets coach Robert Saleh and defensive co-ordinator Jeff Ulbrich's defensive scheme. “Marcus is a valuable member of this organization, someone that started his career here, who’s been a pro’s pro,” Douglas said last week. "Smart, he’s been reliable and he’s provided outstanding leadership. Our plan hasn’t changed. “We are in the process of working to have Marcus be here long term.” Maye's agent Erik Burkhardt made some headlines last week on social media when he criticized the Jets while replying to a Twitter post about the team expecting to have around $80 million to spend on the salary cap this off-season to sign or acquire any players they want. “Yet refuse to take care of their best player, Captain, & team-voted MVP in his prime who had several All-Pro votes,” Burkhardt tweeted last Wednesday, “and who played out his entire rookie deal and even changed positions on his contract year (after they got rid of last yrs All-Pro safety).” Burkhardt was referring to Adams, who was locked in a bitter contract dispute last off-season before being traded to Seattle. Douglas downplayed Burkhardt's comments last Thursday while speaking to reporters. “I have a lot of respect for Erik,” Douglas said. “I think he’s a great person, I’ve had a lot of great conversations with him and you guys know how I feel about Marcus. Look, this is part of the business. This is part of negotiating, but I don’t see this affecting our ability to get something done with Marcus that’s beneficial for both him and the team.” Maye has played in every game the past two seasons, erasing any doubts about his health after a shoulder injury limited him to six games in 2018. He has six career interceptions, 22 passes defenced and 257 total tackles. ___ More AP NFL: https://apnews.com/NFL and https://twitter.com/AP_NFL Dennis Waszak Jr., The Associated Press
VIS, part of ViacomCBS Networks International, has struck a partnership to develop formats and shows with South Korea-based Something Special. The deal expands the corporation’s activities in Korea and the Asian TV markets. Founded at the end of 2019 by Hwang Jin Woo, former president of CJ ENM, and Kim In-soo, former head of formats […]
The U.S. dollar held near a 3 1/2-month high against its rivals on Tuesday as higher bond yields and expectations of faster economic normalisation from the pandemic in the United States put the U.S. currency at an advantage. "Rising U.S. bond yields are obviously driving the dollar but what's behind them is the realisation that U.S. vaccination programme is going ahead very fast and the U.S. economic normalisation may happen earlier than people have expected, perhaps by a quarter or two," said Yukio Ishizuki, senior strategist at Daiwa Securities.
PITTSBURGH, March 08, 2021 (GLOBE NEWSWIRE) -- II-VI Incorporated (Nasdaq: IIVI), a global leader in engineered materials and optoelectronic components, announced today that the Company will hold a live webcast and conference call on Tuesday, March 9, 2021, at 9:00 a.m. EST to discuss II-VI’s proposal to acquire all outstanding shares of Coherent in a cash and stock transaction. The webcast and call will be hosted by Dr. Vincent D. (Chuck) Mattera, Jr., Chief Executive Officer; Mary Jane Raymond, Chief Financial Officer; Dr. Giovanni Barbarossa, Chief Strategy Officer and President, Compound Semiconductors; and Steve Pagliuca, Co-Chairman of Bain Capital. The press release detailing the terms of II-VI’s proposal was issued on Monday, March 8, 2021, and can be viewed on the Company’s website at www.ii-vi.com/investor-relations. The presentation accompanying today’s call can also be found on II-VI’s website. Webcast URL: https://edge.media-server.com/mmc/p/qph439h9 Individuals wishing to participate in the webcast can access the event at the Company’s website by visiting www.ii-vi.com or via https://edge.media-server.com/mmc/p/qph439h9. To join the call and replay: If you wish to participate in the call, please dial (877) 316-5288 for U.S. calls and (734) 385-4977 for international calls. When you call, please enter ID number 8528908 and provide your name and company affiliation. The call will be recorded, and a replay will be available to interested parties who are unable to attend the live event. This service will be available up to 11:59 p.m. EST on Friday, March 12, 2021, by dialing (855) 859-2056 for U.S. calls and (404) 537-3406 for international calls and entering the ID number 8528908. About II-VI Incorporated II-VI Incorporated, a global leader in engineered materials and optoelectronic components, is a vertically integrated manufacturing company that develops innovative products for diversified applications in communications, materials processing, aerospace & defense, semiconductor capital equipment, life sciences, consumer electronics, and automotive markets. Headquartered in Saxonburg, Pennsylvania, the Company has research and development, manufacturing, sales, service, and distribution facilities worldwide. The Company produces a wide variety of application-specific photonic and electronic materials and components, and deploys them in various forms, including integrated with advanced software to support our customers. For more information, please visit us at www.ii-vi.com. Forward-Looking Statements This press release contains forward-looking statements relating to future events and expectations that are based on certain assumptions and contingencies. The forward-looking statements are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it in this release have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and global economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above to prove to be correct; (ii) the risks relating to forward-looking statements and other “Risk Factors” discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020; (iii) the purchasing patterns of customers and end-users; (iv) the timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the Company’s ability to integrate recently acquired businesses and realize synergies, cost savings and opportunities for growth in connection therewith, together with the risks, costs and uncertainties associated with such acquisitions and integration efforts; (vii) the Company’s ability to devise and execute strategies to respond to market conditions; (viii) the risks of business and economic disruption related to the currently ongoing COVID-19 outbreak and any other worldwide health epidemics and outbreaks that may arise; (ix) the outcome of any discussions between the Company and Coherent (“Coherent”) with respect to a possible transaction, including the possibility that the parties will not agree to pursue a business combination transaction or that the terms of any transaction will be materially different from those described herein; (x) the conditions to the completion of the proposed transaction, including the receipt of any required stockholder and regulatory approvals; (xi) the Company’s ability to finance the proposed transaction with Coherent and the substantial indebtedness the Company expects to incur in connection with the proposed transaction, and the need to generate sufficient cash flows to service and repay such debt; (xii) the possibility that the Company may be unable to achieve expected synergies and operating efficiencies within the expected timeframes or at all and to successfully integrate Coherent’s operations with those of the Company; and (xiii) the possibility that such integration may be more difficult, time-consuming or costly than expected or that operating costs and business disruption (including, without limitation, disruptions in relationships with employees, customers or suppliers) may be greater than expected in connection with the proposed transaction. The Company disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events or developments, or otherwise. No Offer or Solicitation This document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. Additional Information and Where to Find It This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. This communication relates to a proposal that II-VI has made for a business combination transaction with Coherent. In furtherance of this proposal and subject to future developments, II-VI (and, if a negotiated transaction is agreed to, Coherent) may file one or more registration statements, proxy statements, tender offer statements or other documents with the SEC. This communication is not a substitute for any proxy statement, registration statement, tender offer statement, prospectus or other document II-VI and/or Coherent may file with the SEC in connection with the proposed transaction. INVESTORS AND SECURITY HOLDERS OF II-VI AND COHERENT ARE URGED TO READ THE PROXY STATEMENT(S), REGISTRATION STATEMENT, TENDER OFFER STATEMENT, PROSPECTUS AND/OR OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Any definitive proxy statement(s) or prospectus(es) (if and when available) will be mailed to stockholders of II-VI and/or Coherent, as applicable. Investors and security holders will be able to obtain free copies of these documents (if and when available) and other documents filed with the SEC by II-VI through the web site maintained by the SEC at www.sec.gov, and by visiting II-VI’s investor relations site at https://ii-vi.com/investor-relations/. Participants in the Solicitation This communication is neither a solicitation of a proxy nor a substitute for any proxy statement or other filings that may be made with the SEC. Nonetheless, II-VI and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. You can find information about II-VI’s executive officers and directors in II-VI’s proxy statement for its 2020 annual meeting, which was filed with the SEC on September 29, 2020 and in II-VI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which was filed with the SEC on August 26, 2020. Additional information regarding the interests of such potential participants will be included in one or more registration statements, proxy statements, tender offer statements or other documents filed with the SEC if and when they become available. These documents (if and when available) may be obtained free of charge from the SEC's website www.sec.gov, and by visiting II-VI’s investor relations site at https://ii-vi.com/investor-relations/. CONTACT: InvestorsMary Jane RaymondChief Financial Officerinvestor.firstname.lastname@example.org/contact-us
Canadians should look to take advantage of a market pullback and add stocks like Lightspeed POS Inc. (TSX:LSPD)(NYSE:LSPD). The post Why a Market Pullback Is the Best Time to Buy Stocks appeared first on The Motley Fool Canada.